These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 20880107

  • 1. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
    Buglio D, Mamidipudi V, Khaskhely NM, Brady H, Heise C, Besterman J, Martell RE, MacBeth K, Younes A.
    Br J Haematol; 2010 Nov; 151(4):387-96. PubMed ID: 20880107
    [Abstract] [Full Text] [Related]

  • 2. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM.
    Clin Cancer Res; 2009 May 15; 15(10):3354-65. PubMed ID: 19417023
    [Abstract] [Full Text] [Related]

  • 3. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
    Jóna A, Khaskhely N, Buglio D, Shafer JA, Derenzini E, Bollard CM, Medeiros LJ, Illés A, Ji Y, Younes A.
    Exp Hematol; 2011 Oct 15; 39(10):1007-1017.e1. PubMed ID: 21767511
    [Abstract] [Full Text] [Related]

  • 4. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
    Hui KF, Chiang AK.
    Int J Cancer; 2014 Dec 15; 135(12):2950-61. PubMed ID: 24771510
    [Abstract] [Full Text] [Related]

  • 5. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z.
    Mol Cancer Ther; 2008 Apr 15; 7(4):759-68. PubMed ID: 18413790
    [Abstract] [Full Text] [Related]

  • 6. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S.
    Blood; 2003 Nov 15; 102(10):3765-74. PubMed ID: 12893773
    [Abstract] [Full Text] [Related]

  • 7. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
    Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N.
    Blood; 2012 Mar 15; 119(11):2579-89. PubMed ID: 22262760
    [Abstract] [Full Text] [Related]

  • 8. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade.
    El-Khoury V, Moussay E, Janji B, Palissot V, Aouali N, Brons NH, Van Moer K, Pierson S, Van Dyck E, Berchem G.
    Mol Cancer Ther; 2010 May 15; 9(5):1349-60. PubMed ID: 20406947
    [Abstract] [Full Text] [Related]

  • 9. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L, Benedetti V, De Cesare M, Corna E, Cincinelli R, Zaffaroni N, Zunino F, Perego P.
    J Inorg Biochem; 2012 Aug 15; 113():94-101. PubMed ID: 22717676
    [Abstract] [Full Text] [Related]

  • 10. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
    Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, Younes A.
    Clin Cancer Res; 2004 May 01; 10(9):3207-15. PubMed ID: 15131062
    [Abstract] [Full Text] [Related]

  • 11. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
    Amengual JE, Johannet P, Lombardo M, Zullo K, Hoehn D, Bhagat G, Scotto L, Jirau-Serrano X, Radeski D, Heinen J, Jiang H, Cremers S, Zhang Y, Jones S, O'Connor OA.
    Clin Cancer Res; 2015 Oct 15; 21(20):4663-75. PubMed ID: 26116270
    [Abstract] [Full Text] [Related]

  • 12. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
    Rosik L, Niegisch G, Fischer U, Jung M, Schulz WA, Hoffmann MJ.
    Cancer Biol Ther; 2014 Jun 01; 15(6):742-57. PubMed ID: 24618845
    [Abstract] [Full Text] [Related]

  • 13. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
    Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A, Younes A.
    Br J Haematol; 2009 Nov 01; 147(4):515-25. PubMed ID: 19775297
    [Abstract] [Full Text] [Related]

  • 14. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 15. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
    Huang H, Liu N, Yang C, Liao S, Guo H, Zhao K, Li X, Liu S, Guan L, Liu C, Xu L, Zhang C, Song W, Li B, Tang P, Dou QP, Liu J.
    PLoS One; 2012 Jun 01; 7(12):e52576. PubMed ID: 23285100
    [Abstract] [Full Text] [Related]

  • 16. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF, Leung YY, Yeung PL, Middeldorp JM, Chiang AK.
    Br J Haematol; 2014 Dec 01; 167(5):639-50. PubMed ID: 25155625
    [Abstract] [Full Text] [Related]

  • 17. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K, Kobayashi Y, Takatoku MA, Ozawa K, Kano Y, Ishii H, Furukawa Y.
    Acta Haematol; 2006 Dec 01; 115(1-2):78-90. PubMed ID: 16424655
    [Abstract] [Full Text] [Related]

  • 18. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 01; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 19. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C.
    Mol Cancer Ther; 2007 Jan 01; 6(1):37-50. PubMed ID: 17237265
    [Abstract] [Full Text] [Related]

  • 20. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ.
    Cancer Res; 2006 Apr 01; 66(7):3773-81. PubMed ID: 16585204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.